E
Algernon Pharmaceuticals Inc.
AGNPF
$0.063
$0.00916.67%
E
Sell
3/18/2024Upgraded
Algernon Pharmaceuticals Inc. (AGNPF) was upgraded to E+ from E on 3/18/2024 due to an increase in the volatility index.
Algernon Pharmaceuticals Inc. (AGNPF) was upgraded to E+ from E on 3/18/2024 due to an increase in the volatility index.
E
Sell
3/1/2024Downgrade
Algernon Pharmaceuticals Inc. (AGNPF) was downgraded to E from E+ on 3/1/2024 due to a decline in the solvency index and volatility index. The quick ratio declined from 0.08 to 0.03.
Algernon Pharmaceuticals Inc. (AGNPF) was downgraded to E from E+ on 3/1/2024 due to a decline in the solvency index and volatility index. The quick ratio declined from 0.08 to 0.03.
E
Sell
1/19/2024Upgraded
Algernon Pharmaceuticals Inc. (AGNPF) was upgraded to E+ from E on 1/19/2024 due to an increase in the volatility index.
Algernon Pharmaceuticals Inc. (AGNPF) was upgraded to E+ from E on 1/19/2024 due to an increase in the volatility index.
E
Sell
1/4/2024Downgrade
Algernon Pharmaceuticals Inc. (AGNPF) was downgraded to E from E+ on 1/4/2024 due to a decline in the solvency index and volatility index. The quick ratio declined from 0.21 to 0.08.
Algernon Pharmaceuticals Inc. (AGNPF) was downgraded to E from E+ on 1/4/2024 due to a decline in the solvency index and volatility index. The quick ratio declined from 0.21 to 0.08.
E
Sell
12/27/2023Upgraded
Algernon Pharmaceuticals Inc. (AGNPF) was upgraded to E+ from E on 12/27/2023 due to an increase in the volatility index.
Algernon Pharmaceuticals Inc. (AGNPF) was upgraded to E+ from E on 12/27/2023 due to an increase in the volatility index.
E
Sell
12/6/2023Downgrade
Algernon Pharmaceuticals Inc. (AGNPF) was downgraded to E from E+ on 12/6/2023 due to a large decline in the growth index, solvency index and volatility index. Operating cash flow declined 65.55% from -$326.3 to -$540.2.
Algernon Pharmaceuticals Inc. (AGNPF) was downgraded to E from E+ on 12/6/2023 due to a large decline in the growth index, solvency index and volatility index. Operating cash flow declined 65.55% from -$326.3 to -$540.2.
E
Sell
3/14/2023Downgrade
Algernon Pharmaceuticals Inc. (AGNPF) was downgraded to E+ from D- on 3/14/2023 due to a decline in the volatility index and total return index.
Algernon Pharmaceuticals Inc. (AGNPF) was downgraded to E+ from D- on 3/14/2023 due to a decline in the volatility index and total return index.
D
Sell
2/2/2023Upgraded
Algernon Pharmaceuticals Inc. (AGNPF) was upgraded to D- from E+ on 2/2/2023 due to a major increase in the growth index. Operating cash flow increased 47.55% from -$1.14M to -$598.7, earnings per share increased from -$0.892 to -$0.5863, and EBIT increased 19.29% from -$1.67M to -$1.35M.
Algernon Pharmaceuticals Inc. (AGNPF) was upgraded to D- from E+ on 2/2/2023 due to a major increase in the growth index. Operating cash flow increased 47.55% from -$1.14M to -$598.7, earnings per share increased from -$0.892 to -$0.5863, and EBIT increased 19.29% from -$1.67M to -$1.35M.
E
Sell
12/19/2022Downgrade
Algernon Pharmaceuticals Inc. (AGNPF) was downgraded to E+ from D- on 12/19/2022 due to a decline in the total return index and volatility index.
Algernon Pharmaceuticals Inc. (AGNPF) was downgraded to E+ from D- on 12/19/2022 due to a decline in the total return index and volatility index.
D
Sell
11/28/2022Downgrade
Algernon Pharmaceuticals Inc. (AGNPF) was downgraded to D- from D on 11/28/2022 due to a large decline in the growth index, volatility index and solvency index. EBIT declined 185.21% from -$586.2 to -$1.67M, earnings per share declined from -$0.3758 to -$0.8925, and operating cash flow declined 56.12% from -$731.6 to -$1.14M.
Algernon Pharmaceuticals Inc. (AGNPF) was downgraded to D- from D on 11/28/2022 due to a large decline in the growth index, volatility index and solvency index. EBIT declined 185.21% from -$586.2 to -$1.67M, earnings per share declined from -$0.3758 to -$0.8925, and operating cash flow declined 56.12% from -$731.6 to -$1.14M.
D
Sell
5/16/2022Upgraded
Algernon Pharmaceuticals Inc. (AGNPF) was upgraded to D from D- on 5/16/2022 due to an increase in the total return index and volatility index.
Algernon Pharmaceuticals Inc. (AGNPF) was upgraded to D from D- on 5/16/2022 due to an increase in the total return index and volatility index.
D
Sell
5/1/2022Downgrade
Algernon Pharmaceuticals Inc. (AGNPF) was downgraded to D- from D on 5/1/2022 due to a decline in the volatility index and solvency index. The quick ratio declined from 4.83 to 1.59.
Algernon Pharmaceuticals Inc. (AGNPF) was downgraded to D- from D on 5/1/2022 due to a decline in the volatility index and solvency index. The quick ratio declined from 4.83 to 1.59.
D
Sell
4/25/2022Upgraded
Algernon Pharmaceuticals Inc. (AGNPF) was upgraded to D from D- on 4/25/2022 due to an increase in the volatility index, total return index and valuation index.
Algernon Pharmaceuticals Inc. (AGNPF) was upgraded to D from D- on 4/25/2022 due to an increase in the volatility index, total return index and valuation index.
D
Sell
1/31/2022Downgrade
Algernon Pharmaceuticals Inc. (AGNPF) was downgraded to D- from D on 1/31/2022 due to a noticeable decline in the growth index, volatility index and total return index. Earnings per share declined from -$0.1152 to -$0.571, and EBIT declined 103.84% from -$425 to -$866.3.
Algernon Pharmaceuticals Inc. (AGNPF) was downgraded to D- from D on 1/31/2022 due to a noticeable decline in the growth index, volatility index and total return index. Earnings per share declined from -$0.1152 to -$0.571, and EBIT declined 103.84% from -$425 to -$866.3.
D
Sell
1/12/2022Upgraded
Algernon Pharmaceuticals Inc. (AGNPF) was upgraded to D from D- on 1/12/2022 due to an increase in the volatility index.
Algernon Pharmaceuticals Inc. (AGNPF) was upgraded to D from D- on 1/12/2022 due to an increase in the volatility index.
D
Sell
12/28/2021Downgrade
Algernon Pharmaceuticals Inc. (AGNPD) was downgraded to D- from D on 12/28/2021 due to a noticeable decline in the total return index, volatility index and solvency index.
Algernon Pharmaceuticals Inc. (AGNPD) was downgraded to D- from D on 12/28/2021 due to a noticeable decline in the total return index, volatility index and solvency index.
D
Sell
11/22/2021Upgraded
Algernon Pharmaceuticals Inc. (AGNPF) was upgraded to D from D- on 11/22/2021 due to an increase in the total return index and volatility index.
Algernon Pharmaceuticals Inc. (AGNPF) was upgraded to D from D- on 11/22/2021 due to an increase in the total return index and volatility index.
D
Sell
11/5/2021Downgrade
Algernon Pharmaceuticals Inc. (AGNPF) was downgraded to D- from D on 11/5/2021 due to a decline in the volatility index, total return index and growth index.
Algernon Pharmaceuticals Inc. (AGNPF) was downgraded to D- from D on 11/5/2021 due to a decline in the volatility index, total return index and growth index.
D
Sell
7/30/2021Upgraded
Algernon Pharmaceuticals Inc. (AGNPF) was upgraded to D from D- on 7/30/2021 due to a noticeable increase in the growth index and solvency index. Earnings per share increased from -$0.013 to -$0.0081, and EBIT increased 27.25% from -$1.82M to -$1.33M.
Algernon Pharmaceuticals Inc. (AGNPF) was upgraded to D from D- on 7/30/2021 due to a noticeable increase in the growth index and solvency index. Earnings per share increased from -$0.013 to -$0.0081, and EBIT increased 27.25% from -$1.82M to -$1.33M.
D
Sell
5/26/2021Downgrade
Algernon Pharmaceuticals Inc. (AGNPF) was downgraded to D- from D on 5/26/2021 due to a noticeable decline in the growth index and total return index.
Algernon Pharmaceuticals Inc. (AGNPF) was downgraded to D- from D on 5/26/2021 due to a noticeable decline in the growth index and total return index.
D
Sell
5/18/2020Upgraded
Algernon Pharmaceuticals Inc. (AGNPF) was upgraded to D from D- on 5/18/2020 due to an increase in the valuation index, total return index and volatility index.
Algernon Pharmaceuticals Inc. (AGNPF) was upgraded to D from D- on 5/18/2020 due to an increase in the valuation index, total return index and volatility index.
D
Sell
5/1/2020Downgrade
Algernon Pharmaceuticals Inc. (AGNPF) was downgraded to D- from D on 5/1/2020 due to a large decline in the growth index, valuation index and efficiency index. Net income declined 375.04% from -$125.8 to -$597.6, earnings per share declined from -$0.0023 to -$0.0081, and EBIT declined 240.65% from -$173.2 to -$590.
Algernon Pharmaceuticals Inc. (AGNPF) was downgraded to D- from D on 5/1/2020 due to a large decline in the growth index, valuation index and efficiency index. Net income declined 375.04% from -$125.8 to -$597.6, earnings per share declined from -$0.0023 to -$0.0081, and EBIT declined 240.65% from -$173.2 to -$590.
D
Sell
3/16/2020Upgraded
Algernon Pharmaceuticals Inc. (BTHCF) was upgraded to D from D- on 3/16/2020 due to an increase in the volatility index and total return index.
Algernon Pharmaceuticals Inc. (BTHCF) was upgraded to D from D- on 3/16/2020 due to an increase in the volatility index and total return index.
D
Sell
2/24/2020Downgrade
Algernon Pharmaceuticals Inc. (BTHCF) was downgraded to D- from D on 2/24/2020 due to a decline in the volatility index.
Algernon Pharmaceuticals Inc. (BTHCF) was downgraded to D- from D on 2/24/2020 due to a decline in the volatility index.
D
Sell
2/6/2020Upgraded
Algernon Pharmaceuticals Inc. (BTHCF) was upgraded to D from D- on 2/6/2020 due to a large increase in the growth index, efficiency index and solvency index. The quick ratio increased from 0.69 to 4.94, earnings per share increased from -$0.0068 to -$0.0023, and net income increased 60.88% from -$321.6 to -$125.8.
Algernon Pharmaceuticals Inc. (BTHCF) was upgraded to D from D- on 2/6/2020 due to a large increase in the growth index, efficiency index and solvency index. The quick ratio increased from 0.69 to 4.94, earnings per share increased from -$0.0068 to -$0.0023, and net income increased 60.88% from -$321.6 to -$125.8.
D
Sell
8/2/2019Downgrade
Algernon Pharmaceuticals Inc. (BTHCF) was downgraded to D- from D on 8/2/2019 due to a decline in the growth index, volatility index and efficiency index. Net income declined 18.8% from -$334.1 to -$396.9, earnings per share declined from -$0.0071 to -$0.0084, and EBIT declined 12.97% from -$325.3 to -$367.5.
Algernon Pharmaceuticals Inc. (BTHCF) was downgraded to D- from D on 8/2/2019 due to a decline in the growth index, volatility index and efficiency index. Net income declined 18.8% from -$334.1 to -$396.9, earnings per share declined from -$0.0071 to -$0.0084, and EBIT declined 12.97% from -$325.3 to -$367.5.
D
Sell
2/1/2019Upgraded
Breathtec Biomedical, Inc. (BTHCF) was upgraded to D from D- on 2/1/2019 due to an increase in the valuation index, volatility index and efficiency index. Total capital increased 347.98% from $1.04M to $4.68M.
Breathtec Biomedical, Inc. (BTHCF) was upgraded to D from D- on 2/1/2019 due to an increase in the valuation index, volatility index and efficiency index. Total capital increased 347.98% from $1.04M to $4.68M.
D
Sell
12/22/2017Upgraded
Breathtec Biomedical, Inc. (BTHCF) was upgraded to D- from E+ on 12/22/2017 due to an increase in the growth index, total return index and efficiency index. Earnings per share increased from -$0.0102 to -$0.0041, and net income increased 59.45% from -$559.5 to -$226.9.
Breathtec Biomedical, Inc. (BTHCF) was upgraded to D- from E+ on 12/22/2017 due to an increase in the growth index, total return index and efficiency index. Earnings per share increased from -$0.0102 to -$0.0041, and net income increased 59.45% from -$559.5 to -$226.9.
E
Sell
11/27/2017Downgrade
Breathtec Biomedical, Inc. (BTHCF) was downgraded to E+ from D- on 11/27/2017 due to a decline in the valuation index.
Breathtec Biomedical, Inc. (BTHCF) was downgraded to E+ from D- on 11/27/2017 due to a decline in the valuation index.
D
Sell
10/17/2017None
Algernon Pharmaceuticals Inc. (AGNPF) was downgraded to D- from U on 10/17/2017.
Algernon Pharmaceuticals Inc. (AGNPF) was downgraded to D- from U on 10/17/2017.
OTC PK
04/11/2025 3:38PM Eastern
Quotes delayed
